A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Objective
Primary Objective: The primary aim of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting. Therefore, the study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of the unlicensed, investigational NCBP CBU.
Secondary Objectives: In patients receiving a non-licensed NCBP CBU (HPC-CORD BLOOD): Assess incidence of transmission of infections Assess incidence of graft rejection Assess incidence of neutrophil engraftment >500 /ul Determine 1 year survival after cord blood transplantation Assess cumulative incidence of acute graft vs. host disease (GVHD) grades II to IV and grades III to IV Assess cumulative incidence of chronic GVHD Determine platelet engraftment of >20,000/ul and >50,000/ul Determine CBU-derived engraftment